1. Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, Yang SC, Cho KS. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy. Yonsei Med J. 2014; 55:316–323.
2. Santos Arrontes D, Fernández Aceñero MJ, García González JI, Martín Muñoz M, Paniagua Andrés P. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008; 179:857–861.
3. Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol. 2013; 190:55–60.
4. Hall SF. A user’s guide to selecting a comorbidity index for clinical research. J Clin Epidemiol. 2006; 59:849–855.
5. Berod AA, Colin P, Yates DR, Ouzzane A, Audouin M, Adam E, Arroua F, Marchand C, Bigot P, Soulié M, et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int. 2012; 110:E1035–E1040.
6. Kang HW, Seo SP, Kim WT, Kim YJ, Yun SJ, Lee SC, Choi YD, Ha YS, Kim TH, Kwon TG, et al. Impact of the ASA physical status score on adjuvant chemotherapy eligibility and survival of upper tract urothelial carcinoma patients: a multicenter study. J Korean Med Sci. 2017; 32:335–342.